Association of early caffeine administration and neonatal outcomes in very preterm neonates

JAMA Pediatrics

Volumn 169, Issue 1, 2015, Pages 33-38

  Lodha, Abhay ^a,f   Seshia, Mary ^b   McMillan, Douglas D ^c   Barrington, Keith ^d   Yang, Junmin ^e   Lee, Shoo K ^e   Shah, Prakesh S ^e  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE;

ARTICLE; BIRTH; BODY WEIGHT; COHORT ANALYSIS; DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GESTATIONAL AGE; HOSPITAL ADMISSION; HUMAN; HYPOTHESIS; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NECROTIZING ENTEROCOLITIS; NERVOUS SYSTEM INJURY; NEWBORN; NEWBORN INTENSIVE CARE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA; RETROSPECTIVE STUDY; APNEA; BRONCHOPULMONARY DYSPLASIA; CANADA; CLINICAL TRIAL; DUCTUS ARTERIOSUS, PATENT; EPIDEMIOLOGY; INFANT; INFANT MORTALITY; MULTICENTER STUDY; TIME; TREATMENT OUTCOME;

APNEA; BRONCHOPULMONARY DYSPLASIA; CAFFEINE; CANADA; DUCTUS ARTERIOSUS, PATENT; GESTATIONAL AGE; HUMANS; INFANT; INFANT MORTALITY; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925030953     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2014.2223     Document Type: Article

References (27)

1. Aranda JV, Beharry K, Valencia GB, Natarajan G, Davis J. Caffeine impact on neonatal morbidities. J Matern Fetal Neonatal Med. 2010;23(suppl 3):20-23.
2. Bancalari E. Caffeine for apnea of prematurity. N Engl J Med. 2006;354(20):2179-2181.
3. Stevenson DK. On the caffeination of prematurity. N Engl J Med. 2007;357(19):1967-1968.
4. Alden ER, Mandelkorn T, Woodrum DE, Wennberg RP, Parks CR, Hodson WA. Morbidity and mortality of infants weighing less than 1,000 grams in an intensive care nursery. Pediatrics. 1972;50(1):40-49.
5. Bhatia J. Current options in the management of apnea of prematurity. Clin Pediatr (Phila). 2000;39(6):327-336.
6. Gray PH, Flenady VJ, Charles BG, Steer PA; Caffeine Collaborative Study Group. Caffeine citrate for very preterm infants: effects on development, temperament and behaviour. J Paediatr Child Health. 2011;47(4):167-172.
7. Schmidt B, Roberts RS, Davis P, et al Caffeine for Apnea of Prematurity Trial Group. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357(19):1893-1902.
8. Spitzer AR. Evidence-based methylxanthine use in the NICU. Clin Perinatol. 2012;39(1):137-148.
9. Bauer J, Maier K, Linderkamp O, Hentschel R. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. Pediatrics. 2001;107(4):660-663.
10. Schmidt B, Roberts RS, Davis P, et al Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112-2121.
11. Schmidt B, Anderson PJ, Doyle LW, et al Caffeine for Apnea of Prematurity (CAP) Trial Investigators. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA. 2012;307(3):275-282.
12. Taha D, Kirkby S, Nawab U, et al. Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants. J Matern Fetal Neonatal Med. 2014.
13. Patel RM, Leong T, Carlton DP, Vyas-Read S. Early caffeine therapy and clinical outcomes in extremely preterm infants. J Perinatol. 2013;33(2):134-140.
14. Davis PG, Schmidt B, Roberts RS, et al Caffeine for Apnea of Prematurity Trial Group. Caffeine for Apnea of Prematurity Trial: benefits may vary in subgroups. J Pediatr. 2010;156(3):382-387.
15. Lee SK, McMillan DD, Ohlsson A, et al. Variations in practice and outcomes in the Canadian NICU Network: 1996-1997. Pediatrics. 2000;106(5):1070-1079.
16. The Canadian Neonatal Network. http://www.canadianneonatalnetwork.org/portal/. Accessed May 19, 2014.
17. Lodha A, Zhu Q, Lee SK, Shah PS; Canadian Neonatal Network. Neonatal outcomes of preterm infants in breech presentation according to mode of birth in Canadian NICUs. Postgrad Med J. 2011;87(1025):175-179.
18. Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAP-II and SNAPPE-II: simplified newborn illness severity and mortality risk scores. J Pediatr. 2001;138(1):92-100.
19. Routine screening cranial ultrasound examinations for the prediction of long term neurodevelopmental outcomes in preterm infants. Paediatr Child Health. 2001;6(1):39-52.
20. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am. 1986;33(1):179-201.
21. Steer PA, Flenady VJ, Shearman A, Lee TC, Tudehope DI, Charles BG. Periextubation caffeine in preterm neonates: a randomized dose response trial. J Paediatr Child Health. 2003;39(7):511-515.
22. Dobson NR, Patel RM, Smith PB, et al. Trends in caffeine use and association between clinical outcomes and timing of therapy in very low birth weight infants. J Pediatr. 2014;164(5):992, e3.
23. Blaustein MP, Golovina VA, Song H, et al. Organization of Ca2+ stores in vascular smooth muscle: functional implications. Novartis Found Symp. 2002;246:125-137, discussion 137-141, 221-227.
24. Wells JN, Kramer GL. Phosphodiesterase inhibitors as tools in cyclic nucleotide research: a precautionary comment. Mol Cell Endocrinol. 1981;23(1):1-9.
25. Whorton AR, Collawn JB, MontgomeryME, Young SL, Kent RS. Arachidonic acidmetabolism in cultured aortic endothelial cells: effect of cAMP and 3-isobutyl-1-methylxanthine. Biochem Pharmacol. 1985;34(1):119-123.
26. Guthrie SO, Gordon PV, Thomas V, Thorp JA, Peabody J, Clark RH. Necrotizing enterocolitis among neonates in the United States. J Perinatol. 2003;23(4):278-285.
27. Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for extubation in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD000139.